<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444752</url>
  </required_header>
  <id_info>
    <org_study_id>CBP-201-WW001</org_study_id>
    <nct_id>NCT04444752</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Efficacy and Safety of CBP-201</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Multi-Centered Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Connect Biopharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Connect Biopharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of
      CBP-201 in adult subjects with moderate to severe atopic dermatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, dose regimen finding study to assess
      the efficacy, safety, and steady-state PK profile of CBP-201 administered to eligible adult
      subjects with moderate to severe atopic dermatitis compared to placebo. CBP-201 is
      administered as a subcutaneous (SC) injection. The study is divided into a treatment period
      of 16 weeks and a follow-up period of 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eczema area and severity index (EASI) percentage change (EASI-overall)</measure>
    <time_frame>From Baseline to Week 16</time_frame>
    <description>Percentage change in EASI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AE)</measure>
    <time_frame>From Screen (Day-45) until end of study at Week 24</time_frame>
    <description>Safety will be assessed on basis of AEs reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Steady-state trough PK profile)</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Whole blood for plasma CBP-201 concentrations will be obtained and analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentrations of IL-4</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Changes from Baseline will be summarized with descriptive statistics in serum levels of IL-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentrations of IL-13</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Changes from Baseline will be summarized with descriptive statistics in serum levels of IL-13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentrations of IgE</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Changes from Baseline will be summarized with descriptive statistics in serum levels of IgE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in whole blood eosinophil counts</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Changes from Baseline will be summarized with descriptive statistics in whole blood eosinophil counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment (IGA)</measure>
    <time_frame>At Week 16</time_frame>
    <description>Proportion of subjects with IGA 0-1 and a reduction of ≥2 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI-50</measure>
    <time_frame>From Baseline at Week 16</time_frame>
    <description>Proportion of subjects achieving ≥ 50% reduction of EASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI-75</measure>
    <time_frame>From Baseline at Week 16</time_frame>
    <description>Proportion of subjects achieving ≥ 75% reduction of EASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI-90</measure>
    <time_frame>From Baseline at Week 16</time_frame>
    <description>Proportion of subjects achieving ≥ 90% reduction of EASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Pruritus Numerical Rating Scale(PP-NRS)</measure>
    <time_frame>From Baseline to Week 16</time_frame>
    <description>Percent change from Baseline in weekly average of PP-NRS score to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AD flares</measure>
    <time_frame>From Baseline through Week 16</time_frame>
    <description>Number of AD flares from baseline through Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with AD flare</measure>
    <time_frame>From Baseline through Week 16</time_frame>
    <description>Number of days with AD flare through Week 16</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Moderate-to-severe Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>CBP-201 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBP-201 Dose 1 subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBP-201 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBP-201 Dose 2 subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBP-201 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBP-201 Dose 3 subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous (SC) injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBP-201</intervention_name>
    <description>CBP-201 subcutaneous(SC) injection.</description>
    <arm_group_label>CBP-201 Dose 1</arm_group_label>
    <arm_group_label>CBP-201 Dose 2</arm_group_label>
    <arm_group_label>CBP-201 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>subcutaneous(SC) injection</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be an adult ≥18 and ≤ 75 years of age at the screening visit (Screening) with atopic
             dermatitis according to American Academy of Dermatology Consensus Criteria,
             (Eichenfield 2014)

          2. Present for at least 1 year prior to the baseline visit (Baseline) with an inadequate
             response, in the judgement of the Investigator, to AD treatment with a topical regimen
             of corticosteroids, phosphodiesterase inhibitors or calcineurin inhibitors, or for
             whom topical treatments are otherwise medically inadvisable (eg, because of important
             side effect or safety risks)

          3. Investigator Global Assessment (IGA) score ≥ 3 at Screening and Baseline.

          4. Eczema Area and Severity Index (EASI) score ≥ 16 at Screening and Baseline

          5. Body Surface Area (BSA) for total AD involvement ≥ 10% at Screening and Baseline

          6. Able and willing to apply a stable dose of a bland emollient twice a day to affected
             areas for at least 7 days before Baseline and to continue for the duration of the
             study

          7. Females of child-bearing potential (FCBP) and males who have not undergone a vasectomy
             must abstain from heterosexual activities or agree to use effective contraception
             throughout the entire study period.

        Exclusion Criteria:

          1. Have any of the following laboratory abnormalities at Screening:

               1. Hemoglobin ≤ 90% of the lower limit of normal range (LLN)

               2. White blood cell (WBC) below the LLN

               3. Neutrophil count below the LLN

               4. Platelet count below the LLN

          2. Have undergone treatment with any of the following:

               1. Topical agents such as corticosteroids, phosphodiesterase (PDE) inhibitors, Janus
                  kinase (JAK) inhibitors, tacrolimus or pimecrolimus within 1 week prior to
                  Baseline. Note that low to medium potency topical corticosteroids (TCS) are
                  permitted after randomization to treat AD flares

               2. Prior treatment with dupilumab or any antibody against IL-4Rα or IL-13

               3. Systemic treatment for AD or other condition with steroids or other
                  immunosuppressive/immunomodulating substances, e.g., cyclosporine,
                  mycophenolate-mofetil, azathioprine, methotrexate or oral Janus kinase (JAK)
                  inhibitors within 4 weeks prior to Baseline. Use of steroid inhalers and nasal
                  corticosteroids is allowed.

               4. Cell depleting agents, e.g. rituximab, within 6 months of Baseline or treatment
                  with other biologics within 5 half-lives (if known) or 3 months prior to baseline
                  visit, whichever is longer

               5. Phototherapy (narrow band ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet
                  A1 [UVA1], psoralen + ultraviolet A [PUVA]), tanning beds, or any other light
                  emitting device (LED), within 4 weeks of Baseline

               6. ≥ 2 bleach baths within 2 weeks of Baseline

               7. Prescription emollient to treat AD (e.g. Atopiclair®, MimyX®, Epicerum®, etc.)
                  within 2 weeks of Baseline

               8. Any investigational drug within 30 days or within 5 half-lives, whichever is
                  longer, before Baseline.

               9. Live (attenuated) vaccine within 8 weeks of Baseline.

              10. Treatment with systemic traditional Chinese medicine (TCM) or herbal medications
                  within 4 weeks before Baseline or treatment with topical TCM or herbal
                  medications within 1 week before Baseline visit

          3. Have any of the following:

               1. Infection requiring treatment with systemic antibiotics, antivirals,
                  antiparasitics, antiprotozoals, or antifungals within 4 weeks before Baseline, or
                  superficial skin infection, such as impetigo, within 2 weeks before the Baseline
                  (subjects may be rescreened after the infection has resolved)

               2. A history of parasitic infection (e.g. helminth), within 6 months of Baseline

               3. Per investigator judgement, known or suspected history of immunosuppression
                  within 6 months of Baseline, including a history of invasive opportunistic
                  infections, such as aspergillosis, coccidioidomycosis, histoplasmosis, human
                  immunodeficiency virus (HIV), listeriosis, pneumocystosis, or tuberculosis,
                  despite infection resolution; or unusually frequent, recurrent or prolonged
                  infections.

               4. Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis
                  (AKC)

               5. A history of malignancy with the following exceptions: completely treated
                  carcinoma in situ of cervix or non-metastatic squamous or basal cell carcinoma of
                  the skin

               6. Positive results at Screening for hepatitis B surface antigen (HBsAg), hepatitis
                  B core antibody (HBcAb) or hepatitis C antibody with positive HCV RNA polymerase
                  chain reaction; positive HIV serology at screening

               7. An allergy to L-histidine, trehalose or Tween (polysorbate) 80

          4. Women must not be pregnant, planning to become pregnant or breast-feed during the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzhou Connect</last_name>
    <role>Study Director</role>
    <affiliation>Suzhou Connect Biopharmaceuticals, Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Malinda Longphre, PhD</last_name>
    <phone>+15105203361</phone>
    <email>mlongphre@connectpharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maryam Yaghini</last_name>
    <phone>+14156106887</phone>
    <email>myaghini@connectpharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Connect Investigative Site 316</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85295</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 310</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 305</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 324</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 301</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 312</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 322</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 323</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 317</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 318</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 325</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 320</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 306</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 308</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 314</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 321</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 304</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 303</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 307</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 313</name>
      <address>
        <city>West Lafayette</city>
        <state>Indiana</state>
        <zip>47906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 311</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 319</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 315</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 309</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 302</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 110</name>
      <address>
        <city>Bruce</city>
        <state>Australian Capital Territory</state>
        <zip>2617</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 107</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 104</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 108</name>
      <address>
        <city>Kanwal</city>
        <state>New South Wales</state>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 105</name>
      <address>
        <city>Kotara</city>
        <state>New South Wales</state>
        <zip>2289</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 102</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 106</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6060</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 103</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 401</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 203</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 202</name>
      <address>
        <city>Havelock North</city>
        <zip>4130</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 204</name>
      <address>
        <city>Tauranga</city>
        <zip>3112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

